TX-UTSA
To expand the understanding and explanation of Alzheimer’s disease, United States businessman James Truchard has given a $5 million USD gift to The University of Texas at San Antonio (UTSA) College of Sciences to establish the Oskar Fischer Project . The initiative will engage the world’s brightest minds in a comprehensive literature review with the goal of synthesizing that information into one simple explanation for the cause of Alzheimer’s disease. The challenge was announced today during the Society for Neuroscience’s annual meeting, an international gathering of nearly 30,000 scientists taking place through Nov. 7 in the United States.
Truchard, retired president and chief executive officer of United States-based technology company National Instruments, conceptualized and established the Oskar Fischer Project to engage the world’s brightest minds. The challenge will award up to $4 million USD in Oskar Fischer Prizes, including a grand prize of $2 million, two second place prizes of $500,000 each and four third place prizes of $250,000 each. Collectively, the monetary awards are the world’s largest prizes of their kind.
Through personal research, Truchard, 75, was introduced to the work of Oskar Fischer (1876-1942), a Jewish pioneer in neuroscience who studied dementia at the same time as Alois Alzheimer. In 1900, Fischer began working at Charles University’s German University, based in Prague. His research led to the identification of senile plaques (then called neuritic plaques), the signature lesions of Alzheimer’s disease.
Fischer hypothesized that the plaques were associated with presbyophrenia, then characterized as a form of senile dementia marked by memory loss, memory distortions and disorientation. He published on 12 patients with plaques and tangles, protein strands that appear during Alzheimer’s disease, in 1907, the same year that Alzheimer published on one patient with early onset Alzheimer’s.
Fischer remained at the German University until he was removed in 1939. Two years later, he was sent to Theresienstadt in Terezín, a way station for Auschwitz and Treblinka. He died in 1942, unable to survive the harsh conditions of the concentration camp.
“A century has passed since Oskar Fischer’s seminal work, and tens of billions have been spent around the world on research and potential cures. Over 130,000 research papers have been published and yet no definitive explanation and cure for Alzheimer’s has been found,” said Truchard. “We need to look at Alzheimer’s as a big complex puzzle with a missing piece. We need a brilliant individual who can take all of the pieces and consider what each offers, and then develop one explanation that fits because it pulls all of the pieces together and makes the puzzle whole.”
According to the World Alzheimer Report 2018 by Alzheimer’s Disease International (ADI), an estimated 50 million people worldwide are living with dementia at a cost of $1 trillion to the global economy. That population is expected to more than triple by the year 2050, according to ADI, which also reports that the global ratio of publications on neurodegenerative disorders versus cancer is just one to 12.
“The Oskar Fischer Project will take a new systems approach to the research on Alzheimer’s, building on the work Oskar Fischer started over a century ago,” said George Perry , chief scientist of the UTSA Brain Health Consortium . “Jim Truchard’s generous gift will create an international forum to assess that work and bring forward an explanation that will advance society’s understanding of the disease.”
The University of Texas at San Antonio, a world leader in brain health research, will incubate the two-year challenge. In the UTSA Brain Health Consortium, 38 of the nation’s brightest scientists are engaged in research on brain mechanisms and therapeutics. The university’s researchers have expertise in neurodegenerative disease, brain circuits and electrical signaling, traumatic brain injury, regenerative medicine and stem cell therapies, medicinal chemistry and drug design, neuroinflammation, and psychology.
“Through Jim Truchard’s support, the Oskar Fischer Project will accelerate our shared mission of unraveling the mysteries of neurodegeneration through engagement with the smartest thinkers around the world,” said UTSA President Taylor Eighmy .
Truchard added, “I truly believe that Alzheimer’s disease is multifaceted; it’s about lifestyle, heredity and brain regression. It’s important to look at all possible solutions. This contest will bring together the world’s best minds to consider the entire story.”
UTSA will work closely with an interdisciplinary committee of outstanding scientists from Texas to award the Oskar Fischer Prizes. The call for proposals will open in February 2019 and will continue through the two-year term of the project.
About The University of Texas at San Antonio
The University of Texas at San Antonio (UTSA) is a public urban serving university specializing in health, cybersecurity, energy, sustainability, and human and social development. With more than 32,000 students, it is the largest university in the San Antonio metropolitan region. UTSA advances knowledge through research and discovery, teaching and learning, community engagement and public service. The university embraces multicultural traditions and serves as a center for intellectual and creative resources as well as a catalyst for socioeconomic development and the commercialization of intellectual property—for Texas, the nation and the world. Learn more online , on Facebook , on Twitter , on Instagram or on UTSA Today .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005017/en/
Contact:
UTSA Joe Izbrand, 210-458-8754 University Communications and Marketing Cell: 210-827-6525 joe.izbrand@utsa.edu
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom